LRFN5 and OLFM4 in Schizoaffective Disorder

Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.

NCT Number	NCT07447960
Lead Sponsor	Elazığ Mental Health and Diseases Hospital
Conditions	Schizoaffective Disorder
Enrollment	120 participants
Start Date	2026-03-02
Primary Completion	2026-05-29 (estimated)
Study Completion	2026-05-29 (estimated)
Updated on ClinicalTrials.gov	2026-03-04